With the increased understanding of tumor types that are regulated by BET/Brd4-associated oncogenes [46,47] and those driven by the Brd4 fusion [48,49], there has been enormous interest in developing novel BET inhibitors for cancer treatment. This evidence concerns the gene DNER and neoplasm.